
ANTX Stock Forecast & Price Target
ANTX Analyst Ratings
Bulls say
AN2 Therapeutics Inc. is advancing its boron-based therapeutic pipeline, particularly with epetraborole, which has shown favorable safety and tolerability in Phase 2 trials for non-tuberculous mycobacterial (NTM) infections. The observed clinically meaningful improvements in quality of life for patients, alongside strong pre-clinical data suggesting efficacy for treating more challenging forms of NTM, bolster the company's position in the biopharmaceutical market. Overall, the potential of epetraborole to become a key therapeutic option, especially for refractory patients, indicates a positive outlook for AN2 Therapeutics's future financial performance and market presence.
Bears say
AN2 Therapeutics Inc. faces significant challenges as it grapples with disappointing clinical trial results that underscore the potential efficacy limitations of its drug candidates, particularly epetraborole. The company has a history of financial losses and lacks a proven track record of profitability, raising concerns about its viability without successful commercialization of its pipeline products. Additionally, there are substantial risks related to litigation, regulatory approvals, and competition, which could impede AN2's ability to develop and bring its drugs to market effectively.
This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ANTX Analyst Forecast & Price Prediction
Start investing in ANTX
Order type
Buy in
Order amount
Est. shares
0 shares